Hermans, C. http://orcid.org/0000-0001-5429-8437
Giangrande, P. L. F.
O’Mahony, B.
de Kleijn, P.
Bedford, M.
Batorova, A.
Blatný, J.
Jansone, K.
Astermark, J.
Crato, M.
d’Oiron, R.
Dougall, A.
Fijnvandraat, K.
Grønhaug, S.
Jiménez-Yuste, V.
Jokić, M.
Lobet, S.
Nolan, B.
Peyvandi, F.
Ryan, A.
,
Article History
Received: 10 February 2020
Accepted: 13 August 2020
First Online: 24 August 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: PG has received consultancy and/or lecture fees from CSL Behring, Novo Nordisk, and Pfizer within the last year. CH has received consultancy and/or lecture fees from Bayer, Takeda, Roche, CSL Behring, NovoNordisk, Pfizer, SOBI, LFB, OctaPharma within the last year. AB received a speaker fee from SOBI, Roche, Shire and Octapharma within last year. MB is currently a member of the Roche/Chugai Haemophilia A Advisory Board and is in receipt of funding from Pfizer for an investigator-initiated research study. JB has received speaker’s fees and/or served as a consultant for NovoNordisk, Shire/Takeda, Sobi, LFB, Pfizer and Roche within last year. BO’M, PdK and KJ state that they have no competing interests to report.